

## Leveraging MEDLINE indexing for pharmacovigilance – Inherent limitations and mitigation strategies



Rainer Winnenbourg<sup>a,1</sup>, Alfred Sorbello<sup>b</sup>, Anna Ripple<sup>a</sup>, Rave Harpaz<sup>c</sup>, Joseph Tønning<sup>b</sup>, Ana Szarfman<sup>b</sup>, Henry Francis<sup>b</sup>, Olivier Bodenreider<sup>a,\*</sup>

<sup>a</sup> Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, USA

<sup>b</sup> US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA

<sup>c</sup> Oracle Health Sciences GBU, 100 Crosby Drive, Bedford, MA 01730, USA

### ARTICLE INFO

#### Article history:

Received 3 November 2014

Revised 30 July 2015

Accepted 25 August 2015

Available online 2 September 2015

#### Keywords:

MEDLINE indexing  
Pharmacovigilance  
Adverse drug events

### ABSTRACT

**Background:** Traditional approaches to pharmacovigilance center on the signal detection from spontaneous reports, e.g., the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS). In order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE.

**Objectives:** (1) To review how the characteristics of MEDLINE indexing influence the identification of adverse drug events (ADEs); (2) to leverage this knowledge to inform the design of a system for extracting ADEs from MEDLINE indexing; and (3) to assess the specific contribution of some characteristics of MEDLINE indexing to the performance of this system.

**Methods:** We analyze the characteristics of MEDLINE indexing. We integrate three specific characteristics into the design of a system for extracting ADEs from MEDLINE indexing. We experimentally assess the specific contribution of these characteristics over a baseline system based on co-occurrence between drug descriptors qualified by *adverse effects* and disease descriptors qualified by *chemically induced*.

**Results:** Our system extracted 405,300 ADEs from 366,120 MEDLINE articles. The baseline system accounts for 297,093 ADEs (73%). 85,318 ADEs (21%) can be extracted only after integrating specific pre-coordinated MeSH descriptors and additional qualifiers. 22,889 ADEs (6%) can be extracted only after considering indirect links between the drug of interest and the descriptor that bears the ADE context.

**Conclusions:** In this paper, we demonstrate significant improvement over a baseline approach to identifying ADEs from MEDLINE indexing, which mitigates some of the inherent limitations of MEDLINE indexing for pharmacovigilance. ADEs extracted from MEDLINE indexing are complementary to, not a replacement for, other sources.

Published by Elsevier Inc.

## 1. Introduction

The timely identification of adverse drug events (ADEs) during the post-approval phase is an important goal of the public health system. Undetected ADEs result in potentially preventable harm to a substantial number of patients and impose a significant burden on the healthcare system [1–4].

While the U.S. Food and Drug Administration (FDA) collects and analyzes drug safety reports through the FDA Adverse Event Reporting System (FAERS) [5], the systematic inventory and collection of ADEs in structured form remains a challenge. Moreover, given well-recognized limitations with such systems [6], pharmacovigilance activities must evolve to encompass novel complementary data streams, in order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes (e.g., [7–9]).

Text mining techniques have been used to extract ADEs from various sources [10]. Several recent and ongoing projects have attempted to extract ADEs from the DailyMed structured product labels (e.g., [11]), unstructured clinical notes, like those in

\* Corresponding author. Tel.: +1 301 435 3246.

E-mail address: [olivier.bodenreider@nih.gov](mailto:olivier.bodenreider@nih.gov) (O. Bodenreider).

<sup>1</sup> Current address: Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA 94305-5479, USA.

electronic health records (e.g., [12–14]), the social media (e.g., [15,16]), from the biomedical literature, especially MEDLINE® (e.g., [17–19]), or a combination of such sources (e.g., [20]).

The biomedical literature contains valuable information about ADEs in the form of case reports, clinical studies, and observational studies. This information enables drug safety evaluators to assess potentially new ADEs, such as those identified through FAERS. In addition, the biomedical literature may contain ADEs that are not detectable through systems such as FAERS, because healthcare practitioners or researchers are more enthusiastic about publishing their ADE-related findings in scientific journals than reporting them to systems such as FAERS. Moreover, MEDLINE is one of the largest and most comprehensive biomedical literature databases with a broad diversity of human, animal, and *in vitro* data presented in a variety of publication types. In contrast to FAERS, MEDLINE also offers the advantage of providing scientific information that spans the entire life cycle of a drug from early pre-market drug development through useful market life. This makes the biomedical literature a very important source of information about ADEs.

Unlike systems such as FAERS, the new data sources that are now being considered for ADE detection, such as the biomedical literature, were not created specifically for ADE-related applications, and therefore necessitate different approaches to uncover ADEs.

In the MEDLINE database, ADEs are not only expressed in natural language form in the title and abstract, but also in structured form through MeSH indexing. In MEDLINE, citations are indexed with Medical Subject Headings (MeSH®) descriptors (or “main headings”), e.g., for diseases or drugs, that are often enriched with qualifiers (or “subheadings”) that express the specific context in which a topic (e.g., the drug *Levofloxacin*) is discussed in a given citation (e.g., *adverse effects*). In addition to text mining techniques, researchers have also leveraged MEDLINE indexing for identifying ADEs. For example, in the context of the EU-ADR project, Avillach et al. have used co-occurring MeSH descriptors and qualifier pairs in MEDLINE citations as the basis for identifying ADEs [21]. Typically, ADEs are identified by the co-occurrence of a drug descriptor qualified by *adverse effects* and a disease descriptor qualified by *chemically induced*.

However, there are complexities and limitations to extracting ADEs from MEDLINE indexing. For example, while most ADEs are indexed through the combination of a disease descriptor and the *chemically induced* qualifier (e.g., *Tendinopathy/chemically induced*), others, because they are more frequent or important, are completely reflected by a descriptor alone (e.g., *Drug-Induced Liver Injury*) and would not be found by searching the corresponding combination (*Liver Diseases/chemically induced*). In practice, detailed knowledge about the characteristics of MEDLINE indexing is essential to complete and accurate retrieval of ADEs.

Although our approach to extracting ADEs from MEDLINE indexing is generally similar to Avillach’s, the goals of the two projects are different. Avillach et al. are primarily interested in detecting known ADEs in MEDLINE, while our goal is to systematically harvest all ADEs from MEDLINE, already known or not, in order to support signal detection in pharmacovigilance. Therefore, our strategy for identifying ADEs tends to be more aggressive and goes beyond the simple co-occurrence of descriptor-qualifier pairs pioneered by Avillach. In a pilot study designed to expand the scope of resources beyond FAERS, we assessed the feasibility of detecting drug-adverse event safety signals for fluoroquinolones through quantitative data mining of MEDLINE indexing terms [22].

The objectives of this work are (1) to review how the characteristics of MEDLINE indexing influence the identification of ADEs; (2) to leverage this knowledge to inform the design of a system for extracting ADEs from MEDLINE indexing; and (3) to assess the

specific contribution of some characteristics of MEDLINE indexing to the performance of this system.

## 2. Background

In this section, we review some of the characteristics of MEDLINE indexing and analyze their influence on the identification of ADEs from MEDLINE indexing. In the course of our research, we have identified nine of these characteristics as potential issues, and have discussed them with MEDLINE indexing specialists at the National Library of Medicine (NLM). The list of these issues is provided in Table 1. Each issue is presented in detail later in this section. We have developed mitigation strategies for three of these issues (1–3), which we have integrated in the design of our system for identifying ADEs from MEDLINE indexing. For the other issues, we provide some recommendations in Section 5.

### 2.1. The chemically induced qualifier is not always necessary to denote ADEs

As mentioned before, qualifiers are often used by MEDLINE indexers to describe the specific aspects of a descriptor discussed in a given article. For example, the qualifier *chemically induced* can be attached to terms representing biological phenomena, diseases, syndromes, congenital abnormalities, or symptoms caused by endogenous or exogenous substances. In the context of adverse drug events, any term with the *chemically induced* qualifier potentially represents a drug-induced manifestation. However, also applicable in this context are terms (predominantly) from the *Chemically-Induced Disorders* (C25 subtree) in MeSH, which represent additional disorders caused by the intentional or unintentional ingestion or exposure to chemical substances, such as pharmaceutical preparations. These descriptors are “pre-coordinated” in the sense that they implicitly denote the *chemically induced* qualifier (e.g., in *Drug-Induced Liver Injury*), and must be used in lieu of the corresponding descriptor-qualifier combination (e.g., *Liver Diseases/chemically induced*) used for most descriptors. It is important to note that a user searching the descriptor-qualifier combination expressed by these descriptors would not retrieve the corresponding citations. The corresponding ADEs would be missed if the search was restricted to descriptors qualified by *chemically induced*. Table 2 lists 19 such descriptors that can be used for indexing ADEs.

### 2.2. The adverse effects qualifier is not the only qualifier to denote ADEs

Sometimes multiple MeSH qualifiers can be logically grouped together. For example, the related qualifiers *poisoning* and *toxicity* are grouped under the broad qualifier *adverse effects*. From a searcher’s perspective this means that all the grouped qualifiers can be retrieved together when searching on the broad qualifier. However, once articles are retrieved for further processing, the exact qualifier is present in the citation. For example, a citation retrieved from a search on *Levofloxacin/adverse effects* may actually contain the index terms *Levofloxacin/toxicity*. Therefore, subsequent filtering of the ADE citations should consider not only the qualifier *adverse effects*, but also the qualifiers it subsumes, namely *poisoning* or *toxicity*. Along the same lines, the qualifier *contraindications* also often denotes ADEs and should be considered.

### 2.3. The ADE context is sometimes borne by a broader term rather than the drug of interest

As mentioned earlier, indicative of an ADE is the presence of a drug entity with specific qualifiers (e.g., *adverse effects*). However,

**Table 1**  
How the characteristics of MEDLINE indexing influence the identification of ADEs.

1	The <i>chemically induced</i> qualifier is not always necessary to denote ADEs
2	The <i>adverse effects</i> qualifier is not the only qualifier to denote ADEs
3	The ADE context is sometimes borne by a broader term rather than the drug of interest
4	ADEs indexed with MeSH are skewed toward case reports
5	MEDLINE does not record a relation between a drug and the manifestation of an adverse event
6	MeSH descriptors sometimes conflate several drugs
7	MEDLINE indexing rules sometimes aggregate multiple drugs under a broader MeSH descriptor
8	Changes to MeSH have consequences on the retrieval of ADEs
9	MEDLINE indexing is not always immediately available at publication time

as shown in Fig. 1, qualifiers can only be attached to descriptors (1), whereas many specific drugs are only represented in MeSH as supplementary concept records (SCR), to which a qualifier cannot be attached directly. SCRs corresponding to drugs can be linked to qualifiers through two different mechanisms. All SCRs have a *Heading Mapped to* relation to at least one descriptor in MeSH (2). For example the SCR *mivacurium* has a *Heading Mapped to* relation to the descriptor *Isoquinolines*. In practice, any citation index containing *mivacurium* will automatically be enriched with the descriptor *Isoquinolines*. In order to qualify the drug SCR (e.g., with *adverse effects*), indexers must link the qualifier to its corresponding descriptor. Therefore, qualifiers added to drug descriptors in a citation also qualify the corresponding drug SCRs in this citation. The second possible link between a drug SCR and a qualifier is through pharmacologic action relations. The *pharmacological action* (PA) descriptors can also be qualified, similar to the *Heading Mapped to* descriptors (3). For example, *mivacurium* might be indexed together with its PA, *Neuromuscular Nondepolarizing Agents*. In this case the qualifier of the PA descriptor also qualifies the corresponding drug SCR.


In some cases, qualifiers denoting ADEs can be found attached to broader descriptors, relative to the drug of interest. Leveraging these indirect associations between a drug of interest and qualifiers may be important in some cases, especially when MeSH indexing has evolved over time, resulting in the creation of more specific descriptors (see *Changes to MeSH have consequences on the retrieval of ADEs*).

#### 2.4. ADEs indexed with MeSH are skewed toward case reports

Although MEDLINE contains and indexes information from various publication types, the majority of indexed ADE information originates from case reports. Case reports and clinical trials have very different foci, reflected in the indexing. While case reports usually focus on one or a few specific ADEs for a drug (which are indexed individually), clinical trial articles tend to report complete safety profiles for the drug. Moreover, efficacy, not safety, is generally the main focus of clinical trials. As a result, safety information from clinical trial articles is generally not indexed. Moreover, case reports tend to capture rather rare and unusual ADEs, in contrast to

**Table 2**  
Pre-coordinated MeSH descriptors implicitly denoting the *chemically induced* qualifier.

Drug-Induced Liver Injury	Drug Eruptions	Drug-Induced Liver Injury, Chronic
Erythema Nodosum	Serotonin Syndrome	Hand-Foot Syndrome
Stevens-Johnson Syndrome	Neuroleptic Malignant Syndrome	MPTP Poisoning
Dyskinesia, Drug-Induced	Neurotoxicity Syndromes	Psychoses, Substance-Induced
Akathisia, Drug-Induced	Anticholinergic Syndrome	Acute Generalized Exanthematous Pustulosis
Asthma, Aspirin-Induced	Drug Hypersensitivity Syndrome	Chemotherapy-Induced Febrile Neutropenia
Abnormalities, Drug-Induced		



**Fig. 1.** Relations between supplementary concept records, descriptors, and pharmacological actions in MeSH.

clinical trials (usually not large enough to detect rare events, since the study populations are usually sized toward efficacy). Conversely, it is unlikely that an overall safety profile for a drug can be derived from case reports alone.

#### 2.5. MEDLINE does not record a relation between a drug and the manifestation of an adverse event

MeSH index terms for a given citation are provided as a flat list and are generally independent of one another. In fact, in the context of adverse events, it should be noted that the MEDLINE indexers have no way to annotate an ADE pair directly, i.e., to link a drug and a disease for this ADE. Instead, the index will contain a drug qualified by *adverse effects* and a disease term qualified by *chemically induced*. Co-occurrence of the two index terms in a citation is no guarantee for the existence of a direct link between them.

The implicit nature of these co-occurrence relationships is especially problematic when ADE articles are indexed with more than one drug or more than one disease term. For example, a recent study on the prevention and management of major side effects of breast cancer drugs is indexed with the adverse events *cardiovascular*, *gastrointestinal*, and *skin diseases*, as well as the antineoplastic agents *lapatinib*, *bevacizumab*, and *trastuzumab* [23]. Without further information, the simplest assumption is that each of the drugs is possibly responsible for each of the ADEs mentioned (cross-product).

#### 2.6. MeSH descriptors sometimes conflate several drugs

MeSH descriptors, which are used for indexing documents in MEDLINE, are in fact small aggregates of concepts, grouped together as needed to support indexing and retrieval [24]. For example, the MeSH descriptor *Citalopram* (D015283) is used for indexing not only the drug citalopram (as expected), but also its stereoisomer, the drug *Escitalopram*. Although *Escitalopram* is arguably a separate drug (with specific brand names), it does not exist in MeSH outside the descriptor *Citalopram*, making it impossible to distinguish between the two drugs on the basis of the index alone.

Nowadays MeSH tends to create distinct descriptors for most major drugs. For example, a descriptor was recently developed

for *Levofloxacin*, distinct from the descriptor *Ofloxacin* under which it was grouped prior to 2014. However, granularity issues still exist for some drugs, such as *Abatacept/Belatacept*, *Dropropizine/Levodropropizine*, and *Sultopride/Amisulpride*.

### 2.7. MEDLINE indexing rules sometimes aggregate multiple drugs under a broader MeSH descriptor

Although MEDLINE indexers usually select the most specific descriptors for the topics discussed in an article, according to the indexing rule “Rule of Three”, a group of three or more specific descriptors must be replaced by one more general descriptor, if these specific terms are treed under the more general one. For example, although an article about fluoroquinolone-associated myasthenia gravis exacerbation [25] mentions several individual fluoroquinolones in its abstract (*levofloxacin*, *moxifloxacin*, *ciprofloxacin*, *ofloxacin*, *gatifloxacin*, *norfloxacin*, and *trovafloxacin*), the article is not indexed with any of these drug terms but with the more general descriptor *Fluoroquinolones* instead.

One consequence of the Rule of Three is that some adverse events are captured at the class level rather than at the level of individual drugs. This problem might be less prominent in case reports, which focus often on fewer individual drugs than, for instance, research and review articles.

### 2.8. Changes to MeSH have consequences on the retrieval of ADEs

The MeSH terminology is not static but evolves over time to reflect changes in biomedical knowledge, as well as terminology editorial policies. As mentioned before, MeSH descriptors sometimes group several related concepts. These groupings change over time as part of the evolution of MeSH.

For example, MeSH treated *Levofloxacin* as an entry term for the descriptor *Ofloxacin*, until the distinct descriptor *Levofloxacin* was created in 2014. Articles indexed from 2014 onwards can be indexed with the descriptor *Levofloxacin*, but earlier articles about levofloxacin are still indexed with the descriptor *Ofloxacin* (see Fig. 2). In the case of *Levofloxacin*, the new descriptor was actually added retrospectively to citations previously indexed with *Ofloxacin*, if the string “levofloxacin” appears in the title or abstract. In many other cases, however, the indexing of older citations is not modified to reflect descriptors recently added to MeSH.

While the retrospective addition of more specific index terms is generally beneficial to retrieval, it also creates some issues. The first issue is ambiguity. In practice, in articles such as this review article from 2009 reporting on seizures associated with *Levofloxacin* [26], it is not possible to distinguish from the indexing between citations about levofloxacin originally indexed with *Ofloxacin*, and to which *Levofloxacin* was later added, and citations natively indexed with both *Ofloxacin* and *Levofloxacin*. Moreover, a second issue arises from the fact that the qualifiers originally attached to the broader descriptor *Ofloxacin* were not transferred to the more specific descriptor *Levofloxacin* when it was retrospectively assigned to the citation. As a consequence, in order to identify ADEs from the indexing, the *adverse effects* qualifier attached to the broader descriptor *Ofloxacin* needs to be considered when extracting the ADEs of *Levofloxacin*. (This issue was discussed earlier under *The ADE context is sometimes borne by a broader term rather than the drug of interest*).

### 2.9. MEDLINE indexing is not always immediately available at publication time

Indexing MEDLINE citations with appropriate MeSH terms is still a dominantly manual process conducted by the indexers and the National Library of Medicine. Although articles are usually

available through PubMed at the time they are provided by the publishers (status PubMed – in process), the time for completing the indexing (status PubMed – indexed for MEDLINE) and quality control can vary from a few days or weeks for articles from journals such as the *Journal of the American Medical Association*, *New England Journal of Medicine*, *Science*, or *Nature*, to several months for articles published in other journals. As full MEDLINE indexing cannot be expected to be immediately available at publication time for all submitted citations, there may be delays in identifying ADEs from some of the most recently submitted articles.

## 3. Materials

### 3.1. MEDLINE

MEDLINE is the U.S. National Library of Medicine's (NLM) premier bibliographic database that contains currently over 23 million references to journal articles in life sciences with a concentration on biomedicine. MEDLINE contains citations from over 5600 worldwide journals in about 40 languages. Since 2005, between 2000 and 4000 completed references are added each day, a total of more than 700,000 in 2013. A distinctive feature of MEDLINE is that the records are indexed with NLM Medical Subject Headings (MeSH) by human expert curators. Each year during November and December, NLM makes the transition to a new year of Medical Subject Headings (MeSH) vocabulary used to index the articles (Year-End-Processing). In this study, we access MEDLINE through PubMed and eUtilities, retrieving citation records in XML format and indexed with MeSH 2014 vocabulary (as of May 2014).

### 3.2. Medical Subject Headings (MeSH)

The Medical Subject Headings (MeSH) is a controlled vocabulary produced and maintained by the NLM [27]. It is used for indexing, cataloging, and searching the biomedical literature in the MEDLINE/PubMed database, and other documents. As of 2014, the MeSH thesaurus includes 27,149 descriptors organized in 16 hierarchies (e.g., *Chemicals and Drugs*). Additionally, MeSH provides about 210,000 supplementary concept records (SCRs), of which many represent chemicals and drugs (e.g., *atorvastatin*). Each SCR is linked to at least one descriptor through a *Heading mapped to* relation (e.g., *atorvastatin* is associated with *Heptanoic Acids* and *Pyroles*). The descriptors mapped to generally denote the chemical structure of the drug. While most chemical descriptors provide a structural perspective on drugs, some descriptors play a special role as they can be used to annotate the functional characteristics of drug descriptors and SCRs through a pharmacologic action relation (e.g., *atorvastatin* is linked to the mechanism of action *Hydroxymethylglutaryl-CoA Reductase Inhibitors* and to the therapeutic use *Anticholesteremic Agents*). MeSH 2014 is used in this study.

### 3.3. RxNorm

RxNorm is a standardized nomenclature for medications produced and maintained by the U.S. National Library of Medicine (NLM) [28]. RxNorm concepts are linked by NLM to multiple drug identifiers for commercially available drug databases and standard terminologies, including MeSH and ATC. RxNorm serves as a reference terminology for drugs in the U.S. The February 2014 version of RxNorm used in this study integrates 11,788 substances, including ingredients (IN) and precise ingredients (PIN). Ingredients generally represent base forms (e.g., *atorvastatin*), while precise ingredients tend to represent esters and salts (e.g., *atorvastatin calcium*). RxNorm also represents clinical drugs, i.e., the drugs relevant to




Fig. 2. Changes to MeSH have consequences on the retrieval of ADEs.

clinical medicine (e.g., *atorvastatin 10 MG Oral tablet*). The relations among the various drug entities are represented explicitly in RxNorm (e.g., between ingredients and clinical drugs). NLM also provides an application programming interface (API) for accessing RxNorm data programmatically [29].

#### 4. Methods and results

In this section, we present the system we have created for extracting ADEs from MEDLINE indexing. In addition to extracting basic co-occurrences between a drug entity, qualified by the *adverse effects* qualifier, and a disease descriptor, qualified by *chemically induced*, we introduce two types of refinement leveraging the characteristics of MEDLINE indexing discussed in Section 2. In the first refinement, we aim to extend the scope of descriptors and qualifiers by adding descriptors which, in the absence of a *chemically induced* qualifier, already denote adverse events (pre-coordinated MeSH descriptors) and capturing all drug entities bearing the ADE context qualified by *adverse effects* and by the qualifiers it subsumes, namely *poisoning* or *toxicity*, as well as *contraindications*. In the second major refinement, we consider indirect links between drug entities and broader drug descriptors bearing the ADE context, attempting to “transfer” the denotation of ADEs to fine-grained drug entities. These two refinements are not modular additions to the system, but rather integral to it. However, we keep provenance information about each ADE we extract, making it possible to analyze the specific contribution of each part of the system. After the system design, we present an evaluation, both quantitative and qualitative, of the specific contribution of the two refinements made to the baseline system.

##### 4.1. System design

Our approach to extracting ADEs from MEDLINE indexing can be summarized as follows. First, we run a query against the MEDLINE database to retrieve all articles that are relevant to adverse drug events. In each article, we identify among the MeSH indexing terms those that represent the drugs and diseases involved in an

ADE. Finally, we extract the drug-manifestation pairs, along with provenance and metadata information (e.g., publication type).

##### 4.1.1. Step 1: Identifying MEDLINE citations corresponding to ADEs

We designed a broad query to be run against the MEDLINE database capturing all citations with at least one drug in the context of *adverse effects* (drug facet) and one *chemically induced* manifestation (manifestation facet). The query is shown in Fig. 3.

**Drug facet.** The first query facet uses the query term *Chemicals and Drugs Category*, which captures all citations indexed with any drug or chemical term. The qualifier *adverse effects*, which also includes the more specific qualifiers of *poisoning* and *toxicity*, restricts to citations in which the drugs or chemicals are indexed in the context of an adverse event. (Of note, PubMed automatically extends the query to the qualifiers subsumed by *adverse effects*.) This query facet also captures citations that discuss *contraindications* of drugs or chemicals. Restricting to *Chemicals and Drugs Category* prevents the query from capturing irrelevant articles, e.g., articles about the adverse events of medical devices.

**Manifestation facet.** The second facet of the search captures citations indexed with at least one manifestation caused by a drug or chemical. The qualifier *chemically induced* is searched unbound to any particular manifestation term. The scope of this facet is broadened by the addition of 19 hand-selected pre-coordinated MeSH descriptors that implicitly denote the *chemically induced* qualifier, e.g., *Drug-Induced Liver Injury*.

Only articles that fulfill the criteria set by both the drug and the manifestation facets of our query are captured. For example, an article indexed with both the descriptor/qualifier combinations *Heparin/adverse effects* and *Thrombosis/chemically induced* would be captured, under the assumption that it contains the ADE pair of *Heparin* and *Thrombosis*. Similarly, an article would be captured containing the descriptor/qualifier combination *Acetaminophen/poisoning* and the pre-coordinated MeSH descriptor *Drug-Induced Liver Injury*.

```

("Chemicals and Drugs Category/adverse effects"[Mesh] OR "Chemicals and Drugs
Category/contraindications"[Mesh])

AND

("chemically induced"[Subheading]

OR

("Drug-Induced Liver Injury"[Mesh:noexp] OR "Drug Eruptions"[Mesh:noexp] OR
"Drug-Induced Liver Injury, Chronic"[Mesh] OR "Erythema Nodosum"[Mesh] OR
"Serotonin Syndrome"[Mesh] OR "Hand-Foot Syndrome"[Mesh] OR "Stevens-Johnson
Syndrome"[Mesh] OR "Neuroleptic Malignant Syndrome"[Mesh] OR "MPTP
Poisoning"[Mesh] OR "Dyskinesia, Drug-Induced"[Mesh] OR "Neurotoxicity
Syndromes"[Mesh:noexp] OR "Psychoses, Substance-Induced"[Mesh:noexp] OR
"Akathisia, Drug-Induced"[Mesh] OR "Acute Generalized Exanthematous
Pustulosis"[Mesh] OR "Anticholinergic Syndrome"[Mesh] OR "Asthma, Aspirin-
Induced"[Mesh] OR "Drug Hypersensitivity Syndrome"[Mesh] OR "Chemotherapy-
Induced Febrile Neutropenia"[Mesh] OR "Abnormalities, Drug-Induced"[Mesh]))

```

Fig. 3. MEDLINE search query to identify citations with adverse drug events in MEDLINE.

The query was executed using the NCBI Entrez Programming Utilities. The resulting list of PubMed IDs was used to retrieve the corresponding MEDLINE records in XML format to be further processed. The search query yielded a MEDLINE subset of 360 k PMIDs updated through May, 2014.

#### 4.1.2. Step 2: Identifying index terms for drugs and manifestations involved in ADEs

In this second step, we identify index terms for drugs and manifestations involved in ADEs among the MEDLINE citations retrieved at Step 1.

**4.1.2.1. Drugs.** For a given citation, we consider as drug candidates all indexed descriptors that are located in the *Chemicals and Drugs* tree in MeSH as well as all supplementary concept records, if any, that are connected to any of these descriptors through *Heading Mapped to* or *pharmacological action* relationships. We leverage information from the MeSH terminology to reconstruct all hierarchical relationships between all drug candidates for a given citation, see Fig. 4. We use the hierarchical information to report only on terms with highest specificity, i.e., the leaf nodes in the reconstructed tree, whereby information from qualifiers, i.e., the active role in *adverse effects*, *poisoning*, *toxicology*, or *contraindications*, can be passed on from higher level terms to their children. For example, if a citation contains the SCR *mivacurium*, the “mapped to” descriptor *Isoquinolines*, and the “pharmacological action” descriptor *Neuromuscular Nondepolarizing Agents*, with relations as depicted in Fig. 1, we identify only the SCR as the ADE drug. Furthermore, this SCR “inherits” the *adverse effects* (AE) qualifier from the “mapped to” descriptor and the PA descriptor, respectively, and will be considered as an involved drug in this citation. Conversely, if a specific drug does not bear the ADE context (directly or indirectly), it is recorded as a concomitant drug.

**4.1.2.2. AE manifestations.** For a given citation, we consider as manifestations of an adverse event all descriptors from the citation’s index that are further qualified by the qualifier *chemically induced*, as well as any of the 19 pre-coordinated descriptors from Table 2.




Fig. 4. Relations between MESH terms representing drugs or drug classes in MEDLINE indexing (SCR: supplementary concept record; MT: “mapped to” descriptor; PA: “pharmacological action” descriptor).

#### 4.1.3. Step 3: Extracting ADE pairs and metadata

In the third component of our system, we extract the ADE pairs based on the entities identified in Step 2, filter them for clinical relevance, and enrich the ADE pairs with metadata information.

**4.1.3.1. ADE pairs.** As mentioned before, ADE pairs are not explicitly given as part of the MEDLINE indexing. Instead, we reconstruct the pairs based on the drugs and event manifestations individually identified in Step 2. We derive the ADE pairs for a given citation by applying the Cartesian product between all specific drugs and all AE manifestations. The role of a given drug in an ADE pair is then classified as either involved or concomitant, based on the presence or absence of the appropriate qualifiers for this drug.

**4.1.3.1.1. Filtering for clinical significance.** In the context of pharmacovigilance of already approved drugs, we define as drugs of interest those clinically relevant drugs that are currently prescribable and available on the U.S. market. However, descriptors from the *Chemicals and Drugs* tree (D tree) and associated supplementary concept records (SCRs) can also denote chemicals (e.g., *carcinogens*, *environmental*), drugs withdrawn from the

market (e.g., *rimonabant*), non-prescribable drugs or products (e.g., *coffee* or *cosmetics*), or drug-classes (e.g., *pyridines*). Mapping the MeSH drugs from ADE pairs to a drug terminology helps distinguish drugs of interest from other entities and thus improves precision of the extraction process. RxNorm is suitable for establishing such a filter, since it provides curated and regularly updated mappings to drugs in MeSH, as well as information such as prescribability and clinical relevance. Since MeSH is integrated in RxNorm, we use the RxNorm API to map the MeSH descriptor and supplementary concept record identifiers of the candidate drug entities to RxNorm concept unique identifiers (RxCUIs). Subsequently, we normalize all RxCUIs to Ingredients (IN), whenever mappings from MeSH drugs were established to precise ingredients (PIN). Finally, to assess clinical relevance of the ingredients, we require that the ingredients be associated with at least one clinical drug (SCD) in the RxNorm graph.

**4.1.3.2. Metadata.** Besides drugs and adverse events, we extract additional information that could be relevant in the context of signal detection for pharmacovigilance. In addition to identifying drugs as involved or concomitant, we systematically collect MeSH terms providing information about species (B01 subtree), gender (“male” or “female”), age groups (M01.060 subtree), publication types (V tree), epidemiologic methods (E05.318 subtree), and the indication of a drug (any descriptor with the qualifier *drug therapy*), whenever available. Additionally, we extract publication dates from various data elements in the XML file of each citation. Based on these data, we can later easily refine the analysis of our data (e.g., restricted to ADEs found in case reports), compare different cohorts within one set (male vs. female, studies in animals vs. humans), or determine when information about a specific ADE was published for the first time.

## 4.2. Experiments

### 4.2.1. Two levels of refinement over the baseline

As mentioned earlier, our approach to extracting ADEs from MEDLINE indexing integrates two levels of refinement over the baseline, namely an extension of the scope of descriptors and qualifiers for ADEs, and the possibility for a drug descriptor to “inherit” the ADE context (qualifier) placed on a broader drug descriptor. The list of features corresponding to each level of refinement is summarized in Table 3. While these refinements are already built into our system, we measure the specific contribution of each level by tracking at which level (*Baseline*, *Extension*, *Inheritance*) a given ADE is extracted.

**4.2.1.1. Baseline.** This is the most restrictive of the three levels and corresponds to a naïve approach to extracting ADEs from MEDLINE indexing (basic co-occurrence of descriptor-qualifier pairs for drugs and manifestations in the context of ADEs).

- The only qualifier we consider for drugs is *adverse effects* [Feature 1 in Table 3]. The qualifier *contraindications*, as well as the two qualifiers grouped under *adverse effects*, namely *poisoning* and *toxicity*, are not considered.
- Manifestations of adverse events are only identified by descriptors qualified by the *chemically induced* qualifier [Feature 14 in Table 3]. The 19 pre-coordinated manifestation descriptors are not considered.
- No indirect inheritance of the ADE context is allowed. In practice, drug descriptors are considered only if they are directly qualified by *adverse effects* [Feature 9 in Table 3]; SCRs inherit the *adverse effects* qualifier only from the descriptors to which they have direct *Heading Mapped to* or *Pharmacologic Action* relations [Features 5–6 in Table 3].

**4.2.1.2. Extension of the scope of descriptors and qualifiers for ADEs.** In addition to all the features of the baseline, we extend the scope of descriptors and qualifiers for ADEs, by allowing additional (unqualified) descriptors and additional qualifiers.

- In addition to the qualifier *adverse effects*, we consider the qualifier *contraindications*, as well as the two qualifiers grouped under *adverse effects*, namely *poisoning* and *toxicity* [Features 2–4 in Table 3].
- In addition to the descriptors qualified by the *chemically induced* qualifier, we consider the 19 pre-coordinated manifestation descriptors [Feature 15 in Table 3].
- As for the baseline, no indirect inheritance of the ADE context is allowed.

**4.2.1.3. Inheritance of the ADE context.** At this level, we apply all the strategies from the *Baseline* and *Extension* levels. Additionally, inheritance of the ADE context (represented by the qualifiers *adverse effects*, *poisoning*, *toxicity*, and *contraindications*) is allowed. In practice, drug descriptors can inherit the ADE context from associated “mapped to” (MT) and “pharmacological action” (PA) descriptors [Feature 10 and 11 in Table 3]. Moreover, both drug descriptors and SCRs can inherit the ADE context from any of their direct or indirect parent descriptors [Feature 7, 8, 12 and 13 in Table 3].

For example, the descriptor *Levofloxacin* can inherit the ADE context from its parent descriptor *Ofloxacin* (Feature 10). In the index for an article about alternatives to the drug *Practolol* [30], the drug inherits the ADE context from the PA *Adrenergic beta-Antagonists*, which is among the index terms for this article, although the asserted PA in MeSH for this drug is *Adrenergic beta-1 Receptor Antagonists*, a child term of *Adrenergic beta-Antagonists* (Feature 13).

### 4.2.2. Specific contribution of each level

In the following we provide a quantitative evaluation of the results of our system, in terms of extracted drugs, manifestations, and ADE pairs, focusing on the specific contribution of each level. Table 4 shows the cumulative results and the relative gain for the three levels.

**4.2.2.1. Baseline.** We retrieve ADEs for 9786 unique MeSH drugs and chemicals, of which 2146 (22%) pass our RxNorm filter for clinical relevance. The relevant drugs are paired with 3007 unique manifestations. In total we harvest 95,911 unique ADE pairs and 297,093 ADE instances from 152,729 citations.

**4.2.2.2. Extension.** This refinement level shows only moderate improvement in terms of unique drugs (+93) and manifestations (+90). However, we retrieve an additional 17,374 (+18%) unique ADE pairs and 85,318 (+29%) ADE instances. More importantly, 45,978 of these ADE instances refer to drug-manifestation pairs that could not be captured at the *Baseline* level. We harvest information from 45,947 additional citations (+30%) that had not been considered in our baseline approach.

**4.2.2.3. Inheritance.** The overall contribution of this level is marginal in comparison to the first two levels. We only retrieve 15 additional drugs and 10 additional manifestations, nonetheless yielding 5267 additional unique ADEs and 22,889 additional ADE instances. Again, 6262 of these ADE instances refer to drug-manifestation pairs that could not be captured at the *Baseline* or *Extension* levels. We harvest information from 205,597 of the 360 k citations retrieved by our broad MEDLINE query. (The remaining 160 k MEDLINE citations may contain ADE pairs for

**Table 3**  
Strategies followed at different levels.

Strategies	Feature ID	Baseline	Extension	Inheritance
Drugs	Chem + Drug/adverse effects	1	+	+
	Chem + Drug/poisoning	2	–	+
	Chem + Drug/toxicity	3	–	+
	Chem + Drug/contraindication	4	–	+
	SCR → MT descr (direct)	5	+	+
	SCR → PA descr (direct)	6	+	+
	SCR → MT descr (indirect)	7	–	–
	SCR → PA descr (indirect)	8	–	–
	MT descr	9	+	+
	MT descr → MT descr (direct)	10	–	–
	MT descr → PA descr (direct)	11	–	–
	MT descr → MT descr (indir.)	12	–	–
	MT descr → PA descr (indir.)	13	–	–
Events	Descr/chemically induced	14	+	+
	19 pre-coordinated Descr	15	–	+

**Table 4**  
Specific contributions of each level (cumulative numbers of ADE instances and the relative gain).

	Baseline	+Extension	+Inheritance
Number of unique drugs or chemicals	9786	14,268 (+46%)	14,712 (+3%)
Number of unique, clinically relevant drugs	2146	2239 (+4%)	2250 (+0.5%)
Number of unique manifestations	3007	3097 (+3%)	3107 (+0.3%)
Number of unique ADE pairs	95,911	113,285 (+18%)	118,552 (+5%)
Number of ADE pair instances	297,093	382,411 (+29%)	405,300 (+6%)
Number of citations	152,729	198,676 (+30%)	205,597 (+4%)

drugs that are not clinically relevant, chemicals, drug combinations, or drug classes, all of which are ignored on purpose by our RxNorm filter).

#### 4.2.3. Evaluation

By measuring the specific contribution of each level, we were able to demonstrate that the two levels of refinement over the baseline yielded significant numbers of additional ADEs, including novel ADEs that could not be captured at previous levels. While these additional levels are obviously productive, we need to evaluate if the ADEs obtained at each level are valid.

In order to evaluate the quality of the ADEs extracted at the *Extension* and *Inheritance* levels, we focus on the novel ADEs extracted at these levels, i.e., unique ADEs that could not be extracted at previous levels. (That is, we do not review additional instances of ADEs already extracted at previous levels). We also evaluate the ADEs extracted at the *Baseline* level. For each ADE, we need to assess whether the MEDLINE citation from which a given ADE is extracted provides evidence for (true positive) or against (false positive) the ADE. We make this determination from the information contained in the title and abstract of the MEDLINE citation and, if necessary, from the full-text article. For this reason, our evaluation was restricted to those ADEs for which the full-text article was available in PubMed Central.

In practice, we randomly selected 100 ADEs for the *Baseline* and *Extension* levels, and 50 for the less productive *Inheritance* level. Two of the authors (OB and AS), physicians by training, manually compared each candidate ADE against the information available in the corresponding articles. Differences in opinion were discussed and the most conservative evaluation was kept in case of disagreement.

Table 5 shows the detailed results of our evaluation. The proportion of ADEs with supporting evidence in the article is 69% for the *Baseline* level, 74% for the *Extension* level, and 48% for the *Inheritance* level.

Together with the evaluation, we also performed a failure analysis to determine the cause of the false positive ADEs. The two most common types of error were the detection of a wrong association and the detection of an association when there was none. These two types of errors account for 73% of all false positive ADEs overall. The proportion of wrong associations is higher at the *Extension* level (46%), while lack of association is more frequent at the *Baseline* level (45%). The highest proportion of wrong associations is observed at the *Inheritance* level (61%).

Wrong associations tend to occur when several drugs and/or several manifestations are mentioned as index terms in a MEDLINE citation. Our strategy of computing the cross-product of the drugs and manifestations as potential ADEs may result in false positives (e.g., if a given manifestation is related to a specific drug, but not to all the drugs indexed in the article). For example, the drug *Procarbazine* is mentioned in the indexing of an article titled “Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin’s disease in adults” [31] because it is part of the MOPP chemotherapy regimen used in the control group. While our method rightly identifies a cardiac toxicity ADE for *Doxorubicin*, *Epirubicin*, and *Mitoxantrone*, it also wrongly identifies an ADE for *Procarbazine*. Lack of association primarily occurs when an article provides evidence for the absence of an ADE, because such articles are indexed similarly to those reporting evidence of an ADE. In fact, in both cases, the articles discuss (potential) adverse events of drugs, which is reflected in the indexing. For example, an article whose conclusion is “This study supports the safety of the treatment of schizophrenia with pramipexole and haloperidol as a combination therapy” [32] is appropriately indexed with *Pramipexole* and *Dyskinesia, Drug-Induced* despite the fact that the authors demonstrate the lack of worsening of extrapyramidal side effects.

As shown in Table 5, there is a striking difference in the proportion of false positive ADEs between the *Baseline* and *Extension* levels (26–31%) on the one hand and the *Inheritance* level (52%) on the other. In fact, the *Inheritance* level was added specifically

**Table 5**

Evaluation of the ADE pairs extracted at the three levels.

Level	# True positive ("evidence for")	# False positive ("evidence against")	Total
Baseline	69	31	100
Extension	74	26	100
Inheritance	24	26	50

for certain types of ADEs, namely ADEs for drugs involving MeSH descriptors that had undergone recent changes (e.g., when *Levofloxacin* was extracted out of the descriptor *Oxfloxacin*, with MEDLINE citations still showing the ADE context attached to the previous indexing, *Oxfloxacin*). We decided to evaluate such ADEs specifically (15 drug descriptors with a recent mention of previous indexing notes, such as *Levofloxacin*) against all other ADEs captured at this level (15 randomly selected drugs), contrasting the number of novel ADEs specifically extracted at the *Inheritance* level in each set. As shown in Fig. 5, the profiles of the two sets are completely different. For the randomly selected drugs, 82% of the ADEs are extracted at the *Baseline* level, whereas 79% of the ADEs are extracted at the *Inheritance* level for the 15 specifically selected descriptors. In other words, for drugs such as *Levofloxacin*, most of the ADEs would be missed if it were not for the *Inheritance* level. Given that the percentage of false positive ADE is higher at the *Inheritance* level, our recommendation is therefore to apply the *Inheritance* level not to all drugs, but only to those MeSH descriptors that have undergone recent changes and for which the ADE context may be borne by another descriptor as a result of these changes.


## 5. Discussion

We outline the significance of our findings, present lessons learned and recommendations, contrast text mining with data mining for ADE extraction, and discuss some limitations and future work.

### 5.1. Significance

In this work we investigated the properties and limitations of MEDLINE indexing for use in pharmacovigilance. We identified nine MEDLINE indexing properties that affect the manner in which ADEs can be identified and extracted. Based on these findings, we proposed a comprehensive approach for the extraction of ADEs from MEDLINE indexing.

Our evaluation reinforces the notion presented in earlier studies that the use of MEDLINE indexing is a viable approach for extracting valuable safety information from the biomedical literature. In addition, we demonstrate that our approach provides an improvement over existing methods for detecting ADEs via MEDLINE indexing. Specifically, we demonstrate that our approach is able to identify additional ADE-related citations and additional ADEs with relatively high precision that would otherwise be unidentified by existing methods. In a recent related study [33], we applied our ADE extraction approach to evaluate MEDLINE's capability for signaling recently labeled adverse events. The findings of that study provide additional support for the value of MEDLINE indexing for pharmacovigilance. Similarly, our pilot investigation of fluoroquinolone drugs also demonstrated the feasibility of using our multi-step ADE extraction approach to generate a highly relevant, ADE-focused subset of MEDLINE data (from a variety of publication types) that could effectively support quantitative data mining for the detection of drug-adverse event safety signals [22].



**Fig. 5.** Relative and absolute contribution at different levels for random and specific drugs.

More specifically, this investigation defines the role played by MEDLINE indexing in support of pharmacovigilance. On the one hand, extracting ADEs from MEDLINE indexing is relatively straightforward, fully automated and can be repeated on a regular basis to monitor the report of new ADEs in the biomedical literature. Moreover, the rich set of metadata attached to a MEDLINE citation (e.g., publication date and type and population characteristics) can easily be extracted along with the ADE and used for fine-grained analysis of the ADE dataset. On the other hand, we point out (and address) some of the inherent limitations of MEDLINE indexing for pharmacovigilance and demonstrate significant improvements over a naïve baseline approach, i.e., co-occurrence of descriptor-qualifier pairs. We also show how the characteristics of MEDLINE indexing contribute to biases in the ADE information extracted from MEDLINE indexing (e.g., underreporting of some ADE types in case reports vs. clinical trials, specific issues with certain drugs due to their representation in the MeSH vocabulary). Understanding these limitations is critical for developing mitigation strategies when possible. At a minimum, biomedical researchers need to be aware of these limitations in order to define the role ADEs from MEDLINE indexing can play in pharmacovigilance together with other sources of information (e.g., spontaneous reports and clinical trials). These biases and limitations are also the reason why an evaluation against reference lists of ADEs would not be meaningful and was not performed as part of this study.

### 5.2. Lessons learned and recommendations

#### 5.2.1. From the experiment

Overall, the simple analysis of co-occurrence of descriptor-qualifier pairs (*Baseline* level) remains a valid strategy for extracting ADEs from MEDLINE indexing. It provides the bulk of the ADEs extracted from MEDLINE indexing, of which 69% were shown to be correct.

However, a significant number of important ADEs are denoted by pre-coordinated MeSH descriptors and could not be identified if only descriptor-qualifier pairs were used (e.g., *Drug-Induced Liver Injury*). We were able to retrieve 17,374 (+18%) additional unique ADE pairs. The quality of ADEs extracted at the *Extension* level is even slightly higher (74% correct) than for the *Baseline* level. These important ADEs could not have been captured at all with an approach limited to simple descriptor-qualifier pairs. A smaller number of ADEs are captured by qualifiers other than *adverse effects*.

For a small number of drugs, ADEs can be captured only by considering indirect links between a specific drug and the broader descriptor bearing the ADE context (*Inheritance* level). While this phenomenon is only marginal overall, it is very important for specific drugs (e.g., *levofloxacin*). However, it should not be applied across the board, as its performance is generally limited (48% correct).

## 5.2.2. From studying the characteristics of MEDLINE indexing

### 5.2.2.1. ADEs indexed with MeSH are skewed toward case reports.

ADEs extracted from MEDLINE are not sufficient for signal detection for pharmacovigilance, as most of the ADEs indexed come from case reports, in which the ADEs reported are not representative of all ADEs. Therefore, the integration of multiple sources of information beyond the biomedical literature is likely to be critical in order to obtain comprehensive drug safety information. MEDLINE indexing should be considered as one source of ADE information, along with spontaneous reporting (FAERS), observational data (from electronic health records), etc.

5.2.2.2. *MEDLINE does not record a relation between a drug and the manifestation of an adverse event.* The overall quality (i.e., signal-to-noise ratio) of the data originating from peer-reviewed and manually indexed articles should be generally higher than, for instance, the quality of the raw data submitted to the FDA Adverse Event Reporting System (FAERS), where consumers might report entire medication lists alongside the list of symptoms they experienced. Overall, despite potential false positives, the ADEs extracted from MEDLINE indexing are expected to be more targeted than those from spontaneous reporting systems.

5.2.2.3. *MeSH descriptors sometimes conflate several drugs.* Although we showed this was a problem for some drugs (e.g., *levofloxacin*), the impact of this characteristic of MeSH indexing is limited overall. Moreover, over the past years, MeSH has created distinct descriptors for most major drugs. However, the evolution of the MeSH vocabulary for drugs that were once conflated into one descriptor should be taken into account for the analysis of specific drugs.

5.2.2.4. *MEDLINE indexing rules sometimes aggregate multiple drugs under a broader MeSH descriptor.* This issue is an indexing issue, independent from the organization of the MeSH vocabulary itself. Although we have not specifically measured its impact, we suspect it is limited overall. Moreover, this rule applies not to specific drugs, but to all MeSH descriptors. Therefore, it should not have introduced any bias toward specific ADEs.

5.2.2.5. *Changes to MeSH have consequences on the retrieval of ADEs.* This issue is a consequence of the evolution of the MeSH vocabulary, especially when drugs that were conflated under the same descriptor become distinct descriptors. As mentioned earlier, while important for specific drugs, the impact of this issue is marginal overall.

5.2.2.6. *MEDLINE indexing is not always immediately available at publication time.* As a consequence, ADEs extracted from MEDLINE indexing cannot be expected to be immediately available at publication time. This lag time must be taken into account when extracting ADEs (or other information) from MEDLINE indexing.

## 5.3. Text mining vs. data mining for ADE extraction

It is worth noting the parallel efforts for extracting ADEs from the biomedical literature, which apply natural language processing (NLP) techniques to article titles and abstracts [17–19]. Given the current state of the art, it is unclear which of the two approaches—MEDLINE indexing versus NLP—is the better approach for extracting ADEs. These two approaches are most likely complementary. Nonetheless, many of the advantages and limitations of MEDLINE indexing versus NLP are apparent. The indexing is readily available, human-curated, is based on the full text of articles (not just abstracts), and does not require the use of complex NLP techniques that are more prone to error. Conversely, applying NLP to article titles and abstracts (or full-text articles when available)

is not limited by the scope and granularity of the MeSH vocabulary or by the NLM annotation rules. The use of NLP is also not limited by time delays resulting from the need for human annotation.

## 5.4. Limitations and future work

### 5.4.1. MeSH vs. other ADE vocabularies

One limitation of this study is that it does not address the comparison between ADEs extracted from MEDLINE indexing (in reference to the MeSH vocabulary) and other sources of ADEs, coded to different vocabularies. For example, the Medical Dictionary for Regulatory Activities (MedDRA) is the terminology most commonly used by regulatory authorities in the pharmaceutical industry and is endorsed for adverse event classification by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) [34]. Such comparison would require a mapping between MeSH and MedDRA. While equivalences between MeSH and MedDRA are available through the Unified Medical Language System (UMLS) Metathesaurus, meaningful comparison between the MEDLINE and FAERS ADEs would require a significant curation effort in order to bridge granularity differences between the two vocabularies. This effort was beyond the scope of this investigation, but will be the object of future work. In addition, the hierarchical structure of MedDRA allows for vertical aggregation of manifestation terms up to the System Organ Class (SOC) level or horizontal aggregation through Standardised MedDRA Queries (SMQs). MeSH only supports vertical aggregation through its hierarchical structure, and is organized to support indexing and retrieval, not pharmacovigilance. Groupings of MeSH descriptors would need to be defined in order to meaningfully aggregate the ADEs extracted from MEDLINE indexing.

Of note, the indexing of drugs with MeSH does not offer the same challenges. Through the integration of MeSH drugs in RxNorm, these drugs are already aligned with other drug classification systems, such as the Anatomical Therapeutic Chemical (ATC) classification system developed by the World Health Organization (WHO). ATC supports the aggregation of drugs into classes on four levels of granularity. It is commonly used for pharmacoepidemiology and in research projects (e.g., EU-ADR). Comparing classes between MeSH and ATC is not as straightforward [35], and exploiting the ADEs extracted from MEDLINE indexing at the level of drug classes (as opposed to individual drugs) remains somewhat challenging.

### 5.4.2. ADE selection for signal generation

It was beyond the scope of this investigation to determine which statistical techniques would be best for analyzing the signal generated from MEDLINE indexing. Similarly, we chose to follow a search and extraction strategy that retrieves a broad set of ADEs for a diverse set of chemicals and drugs from various types of publications and studies. While Avillach filtered out some publication types as non-contributory [21], and Gurulingappa only considered case-reports [17], we chose to be inclusive of all publication types and to capture provenance information, rather than making an *a priori* selection. This strategy provides greater flexibility and supports refinements of the statistical analysis as needed.

## 6. Conclusions

To enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE.

In this investigation, we focused on the extraction of ADEs from MEDLINE indexing. We confirmed that the analysis of

co-occurrence of descriptor-qualifier pairs remains a valid strategy. We proposed significant improvements over a baseline approach, in order to mitigate some of the inherent limitations of MEDLINE indexing for pharmacovigilance. The system we created successfully extracted 405,300 ADE instances from 205,597 MEDLINE citations vs. 297,093 ADE instances from 198,676 citations for the baseline system. We verified that the majority of these additional ADE instances are correct.

ADEs extracted from MEDLINE indexing for pharmacovigilance purposes are complementary to, not a replacement for, other sources. ADEs could not be reliably extracted from MEDLINE indexing if MEDLINE did not provide fine-grained indexing, not only at the level of individual drugs and manifestations, but also reflecting the specific ADE context for these index terms.

## Disclaimer

The findings and conclusions expressed in this report are those of the authors and do not necessarily represent the views of the FDA.

## Conflict of interest

The authors declare they have no conflict of interest.

## Acknowledgments

This work was supported by the Intramural Research Program of the NIH, National Library of Medicine (NLM). This work also received support from the US Food and Drug Administration (FDA) through the Center for Drug Evaluation and Research (CDER) Critical Path Program [interagency agreement with NLM (XLM12011 001)] and from the Office of Translational Sciences at CDER. RW was supported by an appointment to the NLM Research Participation Program administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the National Library of Medicine. RH was employed by Stanford University while conducting this research, and acknowledges support by NIH grant U54-HG004028 for the National Center for Biomedical Ontology and by NIGMS grant GM101430- 01A1.

The authors would like to thank Lou S. Knecht, Deputy Chief, and Susan C. Schmidt, Unit Head Indexing Section, of the Bibliographic Services Division, Library Operations, at the National Library of Medicine (NLM), and the entire Indexing Section for their tremendous help with this project.

## References

- [1] L.M. Khan, Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay—a systematic review, *Eur. J. Clin. Pharmacol.* 69 (12) (2013) 1985–1996.
- [2] R.M. Smyth, E. Gargon, J. Kirkham, L. Cresswell, S. Golder, R. Smyth, et al., Adverse drug reactions in children—a systematic review, *PLoS ONE* 7 (3) (2012) e24061.
- [3] F. Meier, R. Maas, A. Sonst, A. Patapovas, F. Müller, B. Plank-Kiegele, B. Pfistermeister, O. Schöffski, T. Bürkle, H. Dormann, Adverse drug events in patients admitted to an emergency department: an analysis of direct costs, *Pharmacoepidemiol. Drug Saf.* 24 (2) (2015) 176–186, <http://dx.doi.org/10.1002/pds.3663>.
- [4] B.L. Hug, C. Keohane, D.L. Seger, C. Yoon, D.W. Bates, The costs of adverse drug events in community hospitals, *Joint Comm. J. Qual. Patient Safety/Joint Comm. Res.* 38 (3) (2012) 120–126.
- [5] FDA Adverse Event Reporting System (FAERS). <<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm>>.
- [6] R. Harpaz, W. DuMouchel, N.H. Shah, D. Madigan, P. Ryan, C. Friedman, Novel data-mining methodologies for adverse drug event discovery and analysis, *Clin. Pharmacol. Ther.* 91 (6) (2012) 1010–1021.
- [7] P.M. Coloma, M.J. Schuemie, G. Trifiro, R. Gini, R. Herings, J. Hippisley-Cox, et al., Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project, *Pharmacoepidemiol. Drug Saf.* 20 (1) (2011) 1–11.
- [8] R. Platt, M. Wilson, K.A. Chan, J.S. Benner, J. Marchibroda, M. McClellan, The new Sentinel Network—improving the evidence of medical-product safety, *New Engl. J. Med.* 361 (7) (2009) 645–647.
- [9] P.E. Stang, P.B. Ryan, J.A. Racoosin, J.M. Overhage, A.G. Hartzema, C. Reich, et al., Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership, *Ann. Intern. Med.* 153 (9) (2010) 600–606.
- [10] R. Harpaz, A. Callahan, S. Tamang, Y. Low, D. Odgers, S. Finlayson, et al., Text mining for adverse drug events: the promise, challenges, and state of the art, *Drug Safety: Int. J. Med. Toxicol. Drug Exp.* 37 (10) (2014) 777–790.
- [11] M. Kuhn, M. Campillos, I. Letunic, L.J. Jensen, P. Bork, A side effect resource to capture phenotypic effects of drugs, *Mol. Syst. Biol.* 6 (2010) 343.
- [12] K. Haerian, D. Varn, S. Vaidya, L. Ena, H.S. Chase, C. Friedman, Detection of pharmacovigilance-related adverse events using electronic health records and automated methods, *Clin. Pharmacol. Ther.* 92 (2) (2012) 228–234.
- [13] P. LePendu, S.V. Iyer, A. Bauer-Mehren, R. Harpaz, J.M. Mortensen, T. Podchyska, et al., Pharmacovigilance using clinical notes, *Clin. Pharmacol. Ther.* 93 (6) (2013) 547–555.
- [14] P. Warrar, E.H. Hansen, L. Juhl-Jensen, L. Aagaard, Using text-mining techniques in electronic patient records to identify ADRs from medicine use, *Br. J. Clin. Pharmacol.* 73 (5) (2012) 674–684.
- [15] R. Leaman, L. Wojtulewicz, R. Sullivan, A. Skariah, J. Yang, G. Gonzalez, Towards internet-age pharmacovigilance: extracting adverse drug reactions from user posts in health-related social networks, in: *Proceedings of the 2010 Workshop on Biomedical Natural Language Processing*, 2010, pp. 117–125.
- [16] A. Nikfarjam, A. Sarker, K. O'Connor, R. Ginn, G. Gonzalez, Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features, *J. Am. Med. Inform. Assoc.* 22 (3) (2015) 671–681.
- [17] H. Gurulingappa, A. Mateen-Rajput, L. Toldo, Extraction of potential adverse drug events from medical case reports, *J. Biomed. Semantics* 3 (1) (2012) 15.
- [18] K.D. Shetty, S.R. Dalal, Using information mining of the medical literature to improve drug safety, *J. Am. Med. Inform. Assoc.: JAMIA* 18 (5) (2011) 668–674.
- [19] C. Yang, P. Srinivasan, P.M. Polgreen, Automatic adverse drug events detection using letters to the editor, in: *AMIA ... Annual Symposium proceedings/AMIA Symposium, AMIA Symposium 2012, 2012*, pp. 1030–1039.
- [20] S. Yeleswarapu, A. Rao, T. Joseph, V.G. Saipradeep, R. Srinivasan, A pipeline to extract drug-adverse event pairs from multiple data sources, *BMC Med. Inform. Decis. Mak.* 14 (2014) 13.
- [21] P. Avillach, J.C. Dufour, G. Diallo, F. Salvo, M. Joubert, F. Thiessard, et al., Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project, *J. Am. Med. Inform. Assoc.: JAMIA* 20 (3) (2013) 446–452.
- [22] A. Sorbello, R. Harpaz, A. Szarfman, O. Bodenreider, R. Winnenburger, A. Ripple, et al., Detecting drug-adverse event safety signals through quantitative data mining of MEDLINE indexing terms: a pilot study, in: *54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2014*, Poster A-055.
- [23] O. Metzger Filho, K.S. Saini, H.A. Azim Jr., A. Awada, Prevention and management of major side effects of targeted agents in breast cancer, *Crit. Rev. Oncol./Hematol.* 84 (Suppl. 1) (2012) e79–e85.
- [24] S.J. Nelson, W.D. Johnston, B.L. Humphreys, Relationships in medical subject headings (MeSH), in: C.A. Bean, R. Green (Eds.), *Relationships in the organization of knowledge*, Kluwer Academic Publishers, Dordrecht, Boston, 2001, pp. 171–184.
- [25] S.C. Jones, A. Sorbello, R.M. Boucher, Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review, *Drug Safety: Int J Med Toxicol Drug Exp* 34 (10) (2011) 839–847.
- [26] A. Bellon, G. Perez-Garcia, J.H. Coverdale, R.C. Chacko, Seizures associated with levofloxacin: case presentation and literature review, *Eur. J. Clin. Pharmacol.* 65 (10) (2009) 959–962.
- [27] Medical Subject Headings (MeSH). <<http://www.nlm.nih.gov/mesh/>>.
- [28] RxNorm. <<http://www.nlm.nih.gov/research/umls/rxnorm/>>.
- [29] RxNorm API. <<http://rxnav.nlm.nih.gov/>>.
- [30] Alternatives to praxolol – the argument in more detail, *Drug Therap Bull* 13 (23) (1975) 92.
- [31] A. Aviles, N. Arevila, J.C. Diaz Maqueo, T. Gomez, R. Garcia, M.J. Nambo, Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults, *Leuk. Lymphoma* 11 (3–4) (1993) 275–279.
- [32] S. Kasper, C. Barnas, A. Heiden, H.P. Volz, G. Laakmann, H. Zeit, et al., Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy, *Eur. Neuropsychopharm.* 7 (1) (1997) 65–70.
- [33] R. Harpaz, D. Odgers, G. Gaskin, W. DuMouchel, R. Winnenburger, O. Bodenreider, et al., A time-indexed reference standard of adverse drug reactions, *Sci. Data* 1 (2014) 140043.
- [34] ICH guideline E2B (R2), Electronic transmission of individual case safety reports message specification, in: *Final Version 2.3, Document Revision February 1, 2001*.
- [35] R. Winnenburger, O. Bodenreider, A framework for assessing the consistency of drug classes across sources, *J. Biomed. Semantics* 5 (2014) 30.